Notably, high Lp(a) level variability was significantly associated with adverse cardiovascular risk profiles, including a higher prevalence of hypertension, diabetes mellitus, dyslipidemia, and prior stroke, as well as unfavorable laboratory parameters such as lower hemoglobin levels, elevated WBC counts, and increased serum glucose levels. This evidence concerns the gene LPA and metabolic syndrome.